Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in <i>BRCA</i>-mutated <i>HER2</i>-negative metastatic or advanced breast cancer: a network meta-analysis.

In the subgroup analysis according to BRCA mutation type, olaparib was not associated with PFS, and PFS was worse with TPC in the BRCA1 mutation subgroup (olaparib: HR = 0.91, 95% CrI = 0.28–3.01; TPC: HR = 1.68, 95% CrI = 0.72–3.88) compared with talazoparib ( Figure 4E ), both results did not reach statistical significance.

also in 111,027 other papers